 "Top headlines: HDFC Q4 net rises; Pfizer seeks full US approval for vaccine")
SC refuses to interfere in construction of Central Vista amid Covid
The Supreme Court on Friday refused to entertain a plea against deferment of hearing on a PIL seeking direction to halt construction activity at the Central Vista Avenue Redevelopment Project during the prevailing Covid-19 pandemic but gave liberty to petitioners to approach the Delhi High Court for urgent listing of the matter. The apex court was hearing the appeal against the May 4 order of the high court which had listed the PIL for hearing on May 17 saying it wants to first go through what the Supreme Court has deliberated in its judgement of January 5, giving a go ahead to the ambitious project. Read here
HDFC consolidated net profit up 31%
Mortgage lender HDFC Ltd on Friday reported a 31 per cent jump in consolidated net profit at Rs 5,669 crore for the last quarter of the financial year ended March 2021. Total income on the consolidated basis more than doubled to Rs 35,754 crore in January-March period of 2020-21, as against Rs 16,632 crore in same period of 2019-20, HDFC said in a regulatory filing. Read here
RBI asks banks to on-lend to healthcare cos in 30 days
The RBI on Friday asked the banks seeking funding from the special Rs 50,000-crore on-tap liquidity window to on-lend money to the healthcare service providers within 30 days of availing the credit facility. Earlier this week, the RBI had decided to open an on-tap liquidity window of Rs 50,000 crore with tenures of up to three years at the repo rate till March 31, 2022, to boost liquidity for ramping up Covid-19-related healthcare infrastructure and services. Read here
Pfizer seeks full US approval for vaccine
Pfizer Inc. and its partner BioNTech SE have asked U.S. regulators for full approval of their Covid-19 vaccine, a milestone in their effort to make the shot a sustainable revenue source that goes well beyond its current standing as an emergency product. On Friday, the companies became the first vaccine makers to submit a biologics license application to the U.S. Food and Drug Administration. Read here
Pfizer Inc. and its partner BioNTech SE have asked U.S. regulators for full approval of their Covid-19 vaccine, a milestone in their effort to make the shot a sustainable revenue source that goes well beyond its current standing as an emergency product. On Friday, the companies became the first vaccine makers to submit a biologics license application to the U.S. Food and Drug Administration. Read here
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%